These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23537870)

  • 21. Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period.
    Okade H; Funatsu T; Eto M; Furuya Y; Mizunaga S; Nomura N; Mitsuyama J; Yamagishi Y; Mikamo H
    J Infect Chemother; 2014 Jul; 20(7):423-8. PubMed ID: 24802765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.
    Cutts FT; Zaman SM; Enwere G; Jaffar S; Levine OS; Okoko JB; Oluwalana C; Vaughan A; Obaro SK; Leach A; McAdam KP; Biney E; Saaka M; Onwuchekwa U; Yallop F; Pierce NF; Greenwood BM; Adegbola RA;
    Lancet; 2005 Mar 26-Apr 1; 365(9465):1139-46. PubMed ID: 15794968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
    Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
    Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.
    Watson M; Bayley K; Bell JM; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Roche P; Smith HV; Stewart MG; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2003; 27(4):478-87. PubMed ID: 15508501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients.
    Forstner C; Plefka S; Tobudic S; Winkler HM; Burgmann K; Burgmann H
    Vaccine; 2012 Aug; 30(37):5449-52. PubMed ID: 22749594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serotype 19F pneumococcal meningitis in an imunocompetent infant immunized with heptavalent pneumococcal conjugated vaccine Prevenar].
    Isapof A; Delacourt C; Reinert P; Cohen R; Madhi F
    Arch Pediatr; 2009 Aug; 16(8):1133-6. PubMed ID: 19500954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.
    Dagan R; Givon-Lavi N; Zamir O; Sikuler-Cohen M; Guy L; Janco J; Yagupsky P; Fraser D
    J Infect Dis; 2002 Apr; 185(7):927-36. PubMed ID: 11920317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.
    Dagan R; Givon-Lavi N; Zamir O; Fraser D
    Pediatr Infect Dis J; 2003 Jun; 22(6):532-40. PubMed ID: 12799510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
    Metlay JP; Fishman NO; Joffe M; Edelstein PH
    Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term Polish infants.
    Szynczewska E; Chlebna-Sokół D
    Vaccine; 2011 Sep; 29(40):7107-13. PubMed ID: 21803093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
    Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
    Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the pneumococcal conjugate vaccine on pneumococcal carriage in Turkish children.
    Ercan TE; Severge B; Topkaya A; Ercan RG; Altınkaya N
    Pediatr Int; 2011 Apr; 53(2):224-30. PubMed ID: 21501306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.